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Abstract
Primary Sjögren’s syndrome (pSS) is a chronic autoimmune rheumatic disease with symptoms including dryness, fatigue, 
and pain. The previous work by our group has suggested that certain proinflammatory cytokines are inversely related to 
patient-reported levels of fatigue. To date, these findings have not been validated. This study aims to validate this observa-
tion. Blood levels of seven cytokines were measured in 120 patients with pSS from the United Kingdom Primary Sjögren’s 
Syndrome Registry and 30 age-matched healthy non-fatigued controls. Patient-reported scores for fatigue were classified 
according to severity and compared to cytokine levels using analysis of variance. The differences between cytokines in cases 
and controls were evaluated using Wilcoxon test. A logistic regression model was used to determine the most important 
identifiers of fatigue. Five cytokines, interferon-γ-induced protein-10 (IP-10), tumour necrosis factor-α (TNFα), interferon-α 
(IFNα), interferon-γ (IFN-γ), and lymphotoxin-α (LT-α) were significantly higher in patients with pSS (n = 120) compared 
to non-fatigued controls (n = 30). Levels of two proinflammatory cytokines, TNF-α (p = 0.021) and LT-α (p = 0.043), were 
inversely related to patient-reported levels of fatigue. Cytokine levels, disease-specific and clinical parameters as well as pain, 
anxiety, and depression were used as predictors in our validation model. The model correctly identifies fatigue levels with 
85% accuracy. Consistent with the original study, pain, depression, and proinflammatory cytokines appear to be the most 
powerful predictors of fatigue in pSS. TNF-α and LT-α have an inverse relationship with fatigue severity in pSS challenging 
the notion that proinflammatory cytokines directly mediate fatigue in chronic immunological conditions.
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Introduction
Fatigue is a complex and disabling symptom affecting 
between 22 and 30% of the general population resulting 
in reduced quality of life and associated with substantial 
economic cost [1–5]. It is a prominent feature of numer-
ous chronic diseases, particularly rheumatic diseases such 
as primary Sjögren’s syndrome (pSS) [5, 6].
The aetiology of fatigue is complex and likely multi-
factorial, with both biological and psychosocial elements 
contributing towards the perception of fatigue. Regarding 
the biological basis of fatigue, proinflammatory cytokines 
may play a central role [7]. Fatigue is frequently observed 
in immune-mediated inflammatory conditions and following 
infections, as part of a constellation of symptoms termed 
‘sickness behaviour’. An adaptive response to infection, 
sickness behaviour minimises energy expenditure when an 
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organism is in a weakened state following an infection and 
resolves with the resolution of inflammation [7].
Research previously performed by our group investigated 
the relationship between proinflammatory cytokines and 
fatigue in pSS [8]. Howard-Tripp et al. found 14 cytokines 
to be significantly higher in patients with pSS compared to 
non-fatigued controls. When patients with pSS were grouped 
according to fatigue severity, an unexpected inverse rela-
tionship was found between fatigue scores and four pro-
inflammatory cytokines, IP-10, TNF-α, LT-α, and IFN-γ. 
Considering the role cytokines play in the development of 
the initial inflammatory response, our group postulated that 
a potentially maladaptive immune response may contribute 
to the maintenance of persistent fatigue in a chronic inflam-
matory state as observed in conditions such as pSS. A logis-
tic regression model was created using the cytokines and 
clinical and disease-specific parameters, which was able to 
predict fatigue levels with reasonable accuracy (67%). Simi-
lar accuracy was reported using only IP-10 and IFN-γ, along 
with depression and pain scores.
This study aims to validate the previously reported 
paradoxical observation of an inverse association between 
proinflammatory cytokines and patient-reported fatigue 
scores. We measured the serum levels of seven proinflam-
matory cytokines—interferon-γ-induced protein 10 (IP-10), 
tumour necrosis factor-α (TNF-α), lymphotoxin-α (LT-α), 
interferon-γ (IFN-γ), interferon-α (IFN-α), interleukin-
12p70 (IL-12p70), and interleukin-17 (IL-17). Six of these 
were reported to be significantly higher in pSS patients [8] 
including four demonstrating an inverse relationship with 
fatigue levels. In addition, while IFN-α was not found to be 
significantly higher in pSS patients, it has been well docu-
mented as a potential inducer of fatigue [9].
Methods
Experimental design
The objective of this study was to analyse proinflammatory 
cytokine and fatigue levels in patients with pSS to validate 
the previously observed relationship between cytokines and 
fatigue in pSS. Similar to the original study, we used clinical 
and biological data to ascertain the most important predic-
tors of fatigue within this patient group.
Study population
An independent cohort of patients were selected from the 
United Kingdom Primary Sjögren’s Syndrome Registry 
(UKPSSR) [10]. The UKPSSR holds clinical, haematologi-
cal, and demographic data on over 900 patients with pSS 
and 350 healthy controls across 37 centres in the UK. All 
patients on UKPSSR fulfil the American European Con-
sensus Group criteria for classification of pSS. This study 
randomly selected 30 blood samples each from female 
patients with pSS with either minimal, mild, moderate, or 
severe fatigue, using a random number generator, for a total 
of 120 patients. Thirty non-fatigued healthy controls from 
the UKPSSR were also selected. The North West Research 
Ethics Committee granted the ethical approval for this study.
Clinical parameters
The following clinical parameters were collected contempo-
raneously as the biological samples for this study. Fatigue 
severity was measured using the Profile of Fatigue (PROF) 
Questionnaire which has been validated for pSS [11]. Physi-
cal fatigue was scored on a scale of 0–7 to group patients 
into minimal (0–1), mild (2–3), moderate (4–5), and severe 
(6–7) fatigue groups. Controls were screened for the pres-
ence of fatigue using a self-reported questionnaire. None of 
the controls reported the presence of fatigue or autoimmune 
disease. Anxiety and depression were measured using the 
Hospital Anxiety and Depression Score [12].
Disease-specific measures such as the EULAR Sjögren’s 
Syndrome Disease Activity Index (ESSDAI) and the 
EULAR Sjögren’s Syndrome Patient-Reported Index (ESS-
PRI), Schirmer’s test, unstimulated oral salivary flow, and 
the EULAR Sicca Score were also included [13, 14].
Clinical laboratory data including white cell count 
(WCC), lymphocytes, neutrophils, haemoglobin, erythro-
cyte sedimentation rate (ESR), and C-reactive protein (CRP) 
were measured by the NHS laboratory of the recruiting cen-
tre within a day of sample collection.
Cytokine measurement
Proinflammatory cytokines were measured using biobanked 
serum samples from the UKPSSR. Seven cytokines were 
tested: Interferon-γ-induced protein 10 (IP-10), tumour 
necrosis factor-α (TNF-α), lymphotoxin-α (LT-α), 
interferon-γ (IFN-γ), interferon-α (IFN-α), interleukin-
12p70 (IL-12p70), and interleukin-17 (IL-17). Six cytokines 
were analysed with cytometric bead array and IL-17 was 
measured using enzyme-linked immunosorbent assay as 
previously described [9].
Statistical analysis
Patient demographic data and clinical data are presented 
using median and IQR. Statistical significance was deter-
mined using Kruskal–Wallis test. Cytokine levels were log 
transformed prior to analysis of variance, which was used 
to examine the relationship between the cytokine level and 
the corresponding fatigue score.
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Ordinal logistic regression analysis was used to model 
fatigue levels using all cytokines, WCC, lymphocytes, neu-
trophils, ESR, CRP, ESSDAI, and dryness scores, as well 
as depression, pain, and anxiety scores. The tests performed 
on this data set were robust to FDR multiple test correction.
All statistical analyses and graphical visualizations were 
performed using R version 3.1.1 and SAS JMP Pro (Version 
14) Statistical Data Visualisation software [15, 16].
Results
Study population
Patients with pSS were stratified into four groups accord-
ing to their fatigue levels as previously described [9]. All 
patients were female and predominantly Caucasian. When 
comparing fatigue groups, there were statistically significant 
differences between ESSDAI, ESSPRI, EULAR-SS, WCC, 
lymphocytes, and BMI (Table 1). Age, disease, and symp-
tom duration were not significantly different between groups. 
Anti-Ro/La positivity and percentages of each group taking 
immune-altering medications did not differ significantly 
between groups.
Cytokine differences between patients with pSS 
and healthy controls
All proinflammatory cytokines were higher in the pSS popu-
lation than controls: five proinflammatory cytokines, IP-10, 
TNFα, LTα, IFN-y, and IFNα, were significantly higher in 
patients with pSS compared to controls, and IL-12p70 was 
also close to statistical significance (see Fig. 1).
Cytokine and fatigues scores in pSS
All four of the cytokines evaluated in the original study—
IP-10, IFN-y, TNF-α, and LT-α—showed an inverse rela-
tionship with patient-reported levels of fatigue. This was 
statistically significant for TNF-α (p = 0.021) and LT-α 
(p = 0.043). Overall, the previously reported trend of higher 
cytokine levels associated with reduced fatigue scores in pSS 
patients was replicated—see Fig. 2.
Table 1  Clinical summary for 
the four separate pSS fatigue 
groups demonstrating mean 
and standard deviation for key 
demographics, haematological, 
and clinical variables
Bold p values indicate statistical significance (< 0.05)
Minimal Mild Moderate Severe p value
Age (years) 53 ± 13 58 ± 14 60 ± 12 56 ± 12 Ns
Disease duration (years) 4.4 ± 5.5 7.0 ± 7.7 4.3 ± 4.9 5.1 ± 7.3 Ns
Symptom duration (years) 9 ± 7 12 ± 9 9 ± 7 9 ± 8 Ns
BMI (kg/m2) 26 ± 5 24 ± 4 26 ± 6 30 ± 7 0.0017
% not taking immune-altering medications 43 23 30 20 Ns
% on hydroxychloroquine 33 43 40 46 Ns
% on prednisolone 7 10 7 20 Ns
% on ‘other’ immune-altering medications 13 24 33 14 Ns
ESSDAI 2.8 ± 2.9 3.3 ± 3.4 3.4 ± 3.7 4.8 ± 3.4 Ns
ESSPRI 2.6 ± 1.6 4.6 ± 1.3 5.8 ± 1.6 8.3 ± 1.0 < 0.0001
ESSPRI pain 0.8 ± 0.8 3.4 ± 0.8 5.0 ± 0.8 6.5 ± 0.5 < 0.0001
ESSPRI dryness 1.3 ± 1.2 3.5 ± 0.9 4.9 ± 0.8 6.3 ± 0.7 < 0.0001
EULAR-SS 3.8 ± 2.5 5.4 ± 2.3 5.9 ± 2.1 8.1 ± 1.6 < 0.0001
HADS anxiety (0–21) 4.4 ± 3.2 8.3 ± 3.9 8.9 ± 4.3 10.5 ± 5.2 < 0.0001
HADS depression (0–21) 2.4 ± 2.5 4.9 ± 3.1 6.6 ± 3.2 10.6 ± 4.2 < 0.0001
Ro+/La+ 15 22 14 17 Ns
Ro+/La− 8 5 6 7 Ns
Ro−/La+ 1 1 0 0 Ns
Ro−/La− 4 1 9 6 Ns
Hb (g/dL) 13 ± 0.9 13 ± 0.9 13 ± 1.3 13 ± 1.2 Ns
WCC (× 109/L) 5.0 ± 1.3 5.0 ± 1.2 5.6 ± 2.0 6.6 ± 2.6 0.0042
Neutrophil (× 109/L) 3.0 ± 1.0 3.1 ± 0.9 3.3 ± 1.3 3.7 ± 1.6 Ns
Lymphocyte (× 109/L) 1.4 ± 0.6 1.3 ± 0.4 1.6 ± 0.6 1.8 ± 0.6 0.0095
ESR (mm/h) 27 ± 21 22 ± 18 23 ± 20 24 ± 23 Ns
CRP (mg/L) 1.7 ± 5.2 1.8 ± 5.8 2.2 ± 3.0 4.1 ± 5.6 Ns
IgG (mg/dL) 18 ± 8 16 ± 9 15 ± 7 14 ± 5 Ns
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Cytokine Controls n = 30 pSS cases n = 120 p Value
Median
25th, 75th cenle (pmol/L)
IP-10 431.76
251.44, 601.49
684.09
468.86, 1030.105
0.0001
TNF-α 0.25
0.00, 4.3
5.29
0.00, 13.06
0.0071
LT-α 0.00
0.00, 0.00
0.00
0.00, 5.855
0.0031
IFN-y 0.00
0.00, 30.585
28.34
0.00, 67.59
0.0037
IFN-α 0.00
0.00, 0.025
0.00
0.00, 7.395
0.0140
IL-17 190.9167
128, 269.5
209.4167
142.9167, 299.2925
0.4056
IL-12p70 0.00
0.00, 2.045
0.00
0.00, 5.055
0.0516
B
Cytokine Minimal Mild Moderate Severe p Value
IP-10 725.78
520.89, 1079.83
759.69
571.805, 1139.695
749.52
412.445, 946.965
636.66
433.035, 941.62
0.5984
TNF-α 8.83
0.00, 29.98
7.93
0.00, 22.23
0.00
0.00, 7.49
4.38
0.00, 8.195
0.0214
LT-α 1.11
0.00, 17.535
0.00
0.00, 11.46
0.00
0.00, 1.135
0.00
0.00, 2.53
0.0426
IFN-γ 28.39
0.00, 80.43
36.18
0.00, 82.39
31.73
0.00, 58.11
18.85
0.00, 65.32
0.9526
IFN-α 0.00
0.00, 10.685
0.00
0.00, 10.15
0.00
0.00, 2.82
0.00
0.00, 3.98
0.1156
IL-17 194.5
129.9325, 301.5
206.25
149.375, 289.5
204.8333
157.5, 313.75
223.8333
153, 341.5
0.5559
IL-12p70 4.99
2.98, 6.5
0.00
0.00, 3.565
0.00
0.00, 4.16
0.00
0.00, 3.78
0.0608
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Proinflammatory cytokines and fatigue severity 
in pSS
Given the replication of an inverse relationship between 
proinflammatory cytokines and fatigue in pSS patients, we 
ran an additional analysis as in the original paper [8]. This 
logistic regression model was originally used to establish 
whether fatigue levels could be identified using cytokines, 
disease-specific and clinical parameters as well as pain, 
anxiety, and depression. We repeated this analysis by ini-
tially examining whether cytokines and/or covariates could 
successfully identify fatigue category. We then looked at 
the effect of each cytokine on the model. The full model, 
including all seven cytokines, was able to correctly identify 
fatigue category in 85% of cases (Fig. 2). This model with 
all parameters was sensitive to the presence or absence of 
cytokines, depression, anxiety, and pain, but was robust to 
the presence or absence of other markers of disease activity 
(WCC, neutrophils, ESR, CRP, ESSDAI, and dryness). We 
ran a reduced model including the covariates depression, 
anxiety, and pain alongside LT-α and TNF-α. The reduced 
model correctly identified fatigue category in 85% of cases, 
comparable to the full model. The cytokines IP-10, LT-α, 
IFN-γ, and IL-17 demonstrated the same inverse relationship 
with fatigue category.
Discussion
Our study confirms that pSS patients with higher levels of 
fatigue had lower levels of the proinflammatory cytokines 
than patients with pSS with lower levels of fatigue. This 
inverse relationship was observed for all four of the origi-
nal cytokines, though it was statistically significant only for 
LT-α and TNF-α.
LT-α and TNF-α are closely related cytokines and are 
both produced by an activated Th1 response. Howard-Tripp 
et al. discussed the possibility that dysregulation of Th1 
responses could be affiliated with the development of fatigue 
with the potential that Th2 responses could be important 
in maintaining fatigue, as demonstrated in CFS [17]. The 
cytokine abnormalities in CFS, however, have been incon-
sistent, possibly complicated by confounding psychosocial 
factors.
There is a documented association between Type 1 
IFN signature, often implicated in the pathogenesis of 
pSS, and TNF-α in autoimmune disease [18]. Data from 
our research group, however, has recently demonstrated 
no association with IFN-α or Type I IFN signature with 
fatigue in pSS [19]. Equally, our findings of the relation-
ship between TNF-α and fatigue would explain the failure 
in fatigue reduction in patients treated with anti-TNF-α 
medications [20].
Taken together, our data from this and previous study do 
not support the simple concept of higher levels of inflam-
mation leading to worse fatigue. Instead, we propose that 
regulatory mechanisms of inflammation may be responsible 
for the maintenance of fatigue after the initial proinflamma-
tory response. The presence of persistent immune challenge 
results in chronic inflammation, which may triggers an inap-
propriate or exaggerated anti-inflammatory response. Such 
anti-inflammatory mechanisms may in turn have a role in the 
persistence of fatigue. In other words, we postulated that the 
exaggerated or inappropriate immune regulation turns what 
was an adaptive behavioural response, sickness behaviour, 
into a persistent, pathological response resulting in chronic 
fatigue with or without concomitant pain and depression. 
Identifying such anti-inflammatory mechanisms may give 
clue to treatment of fatigue in pSS.
The strengths of this validation study include (1) a large, 
clinically well-defined patient group; (2) minimal demo-
graphic variation between fatigue groups in the pSS cohort; 
(3) the use of validated measures in pSS; and (4) consistency 
of methods with the original study.
Limitations of this study include the (1) cross-sectional 
nature of this study; (2) fluctuations of cytokine levels 
could be influenced by multiple factors; (3) while the origi-
nal findings have been validated in an independent cohort 
taken from the UKPSSR, a full external validation in another 
cohort is needed; and (4) using an all-female cohort, similar 
to the original study, while minimising the potential gender 
differences in cytokine profile, means our findings may not 
be generalisable to men with pSS.
Conclusion
This study has validated our previous observation of an 
inverse relationship between proinflammatory cytokines and 
fatigue levels in pSS. Our data further challenges the notion 
that proinflammatory cytokines directly mediate fatigue in 
pSS. Further studies to determine whether the model also 
applies to other chronic immune-mediated inflammatory 
conditions and to explore the possible mechanisms of this 
inverse relationship between proinflammatory cytokines and 
fatigue levels are warranted.
Fig. 1  a Table of proinflammatory cytokine levels in patients with 
pSS. Values in the table represent median and 25th, 75th centile 
(pmol/L). Bold typeface indicates statistical significance of cytokine 
serum level between fatigue groups as determined by ANOVA. b Pro-
inflammatory cytokine levels in patients with pSS. Values in the table 
represent median and 25th, 75th centile (pmol/L). Bold typeface indi-
cates statistical significance of cytokine serum level between fatigue 
groups as determined by ANOVA
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Fig. 2  Observed and predicted fatigue levels for the ordinal logistic 
regression model with all seven cytokines, WCC, lymphocytes, neu-
trophils, ESR, CRP, ESSDAI scores, dryness scores, depression, pain, 
and anxiety. This full model predicts fatigue level correctly in 85% of 
cases
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